Gilead Sciences annual debt-to-ebitda ratio
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Debt-to-EBITDA Ratio Growth & History (GILD)
Gilead Sciences's debt-to-ebitda ratio was 2.00 for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.00 | −4.15 | −67.53% |
| 2024 | 2024-12-31 | 6.15 | 3.65 | +145.88% |
| 2023 | 2023-12-31 | 2.50 | −0.23 | −8.39% |
| 2022 | 2022-12-31 | 2.73 | 0.45 | +19.54% |
| 2021 | 2021-12-31 | 2.28 | −3.49 | −60.47% |
| 2020 | 2020-12-31 | 5.78 | 0.20 | +3.65% |
| 2019 | 2019-12-31 | 5.57 | 2.33 | +71.91% |
| 2018 | 2018-12-31 | 3.24 | 0.91 | +38.79% |
| 2017 | 2017-12-31 | 2.34 | 0.86 | +57.93% |
| 2016 | 2016-12-31 | 1.48 | 0.49 | +49.93% |
| 2015 | 2015-12-31 | 0.99 | 0.18 | +22.45% |
| 2014 | 2014-12-31 | 0.81 | −0.63 | −43.82% |
| 2013 | 2013-12-31 | 1.43 | −0.54 | −27.52% |
| 2012 | 2012-12-31 | 1.98 | 0.04 | +2.26% |
| 2011 | 2011-12-31 | 1.93 | 0.93 | +91.76% |
| 2010 | 2010-12-31 | 1.01 | 0.69 | +212.33% |
| 2009 | 2009-12-31 | 0.32 | −0.08 | −20.08% |
| 2008 | 2008-12-31 | 0.40 | — | — |
Gilead Sciences quarterly debt-to-ebitda ratio
Q4.09
Q1.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 95.79 | 93.48 | +4058.53% |
| Q1 2026 | 2026-03-31 | 1.69 | −0.58 | −25.56% |
| Q4 2025 | 2025-12-31 | 2.00 | −4.15 | −67.53% |
| Q3 2025 | 2025-09-30 | 1.88 | −11.35 | −85.79% |
| Q2 2025 | 2025-06-30 | 2.30 | −3.42 | −59.73% |
| Q1 2025 | 2025-03-31 | 2.27 | −4.57 | −66.83% |
| Q4 2024 | 2024-12-31 | 6.15 | 3.65 | +145.88% |
| Q3 2024 | 2024-09-30 | 13.23 | 10.92 | +472.73% |
| Q2 2024 | 2024-06-30 | 5.72 | 3.40 | +146.25% |
| Q1 2024 | 2024-03-31 | 6.84 | 4.56 | +199.95% |
| Q4 2023 | 2023-12-31 | 2.50 | −0.23 | −8.39% |
| Q3 2023 | 2023-09-30 | 2.31 | −0.81 | −25.88% |
| Q2 2023 | 2023-06-30 | 2.32 | −0.56 | −19.41% |
| Q1 2023 | 2023-03-31 | 2.28 | −0.54 | −19.09% |
| Q4 2022 | 2022-12-31 | 2.73 | 0.45 | +19.54% |
| Q3 2022 | 2022-09-30 | 3.12 | 1.08 | +52.88% |
| Q2 2022 | 2022-06-30 | 2.88 | 0.27 | +10.51% |
| Q1 2022 | 2022-03-31 | 2.82 | −2.07 | −42.39% |
| Q4 2021 | 2021-12-31 | 2.28 | −3.49 | −60.47% |
| Q3 2021 | 2021-09-30 | 2.04 | −8.55 | −80.74% |
| Q2 2021 | 2021-06-30 | 2.61 | — | — |
| Q1 2021 | 2021-03-31 | 4.89 | −0.24 | −4.72% |
| Q4 2020 | 2020-12-31 | 5.78 | 0.20 | +3.65% |
| Q3 2020 | 2020-09-30 | 10.59 | 5.02 | +90.25% |
| Q1 2020 | 2020-03-31 | 5.13 | 1.95 | +61.25% |
| Q4 2019 | 2019-12-31 | 5.57 | 2.33 | +71.91% |
| Q3 2019 | 2019-09-30 | 5.56 | 2.96 | +113.79% |
| Q2 2019 | 2019-06-30 | 3.08 | 0.52 | +20.52% |
| Q1 2019 | 2019-03-31 | 3.18 | 0.96 | +42.92% |
| Q4 2018 | 2018-12-31 | 3.24 | 0.91 | +38.79% |
| Q3 2018 | 2018-09-30 | 2.60 | 0.78 | +43.03% |
| Q2 2018 | 2018-06-30 | 2.55 | 0.98 | +61.80% |
| Q1 2018 | 2018-03-31 | 2.23 | 0.67 | +43.22% |
| Q4 2017 | 2017-12-31 | 2.34 | 0.86 | +57.93% |
| Q3 2017 | 2017-09-30 | 1.82 | 0.42 | +30.29% |
| Q2 2017 | 2017-06-30 | 1.58 | 0.50 | +46.70% |
| Q1 2017 | 2017-03-31 | 1.55 | 0.54 | +52.68% |
| Q4 2016 | 2016-12-31 | 1.48 | 0.49 | +49.93% |
| Q3 2016 | 2016-09-30 | 1.40 | 0.34 | +32.27% |
| Q2 2016 | 2016-06-30 | 1.08 | 0.43 | +66.06% |
| Q1 2016 | 2016-03-31 | 1.02 | 0.32 | +46.01% |
| Q4 2015 | 2015-12-31 | 0.99 | 0.18 | +22.45% |
| Q3 2015 | 2015-09-30 | 1.06 | 0.29 | +37.00% |
| Q2 2015 | 2015-06-30 | 0.65 | −0.32 | −32.77% |
| Q1 2015 | 2015-03-31 | 0.70 | −0.78 | −52.90% |
| Q4 2014 | 2014-12-31 | 0.81 | −0.63 | −43.82% |
| Q3 2014 | 2014-09-30 | 0.77 | −0.82 | −51.62% |
| Q2 2014 | 2014-06-30 | 0.96 | −0.67 | −40.93% |
| Q1 2014 | 2014-03-31 | 1.48 | −0.34 | −18.72% |
| Q4 2013 | 2013-12-31 | 1.43 | −0.54 | −27.52% |
| Q3 2013 | 2013-09-30 | 1.59 | −0.64 | −28.59% |
| Q2 2013 | 2013-06-30 | 1.63 | −0.71 | −30.25% |
| Q1 2013 | 2013-03-31 | 1.82 | −0.63 | −25.69% |
| Q4 2012 | 2012-12-31 | 1.98 | 0.04 | +2.26% |
| Q3 2012 | 2012-09-30 | 2.23 | 2.23 | +550519.79% |
| Q2 2012 | 2012-06-30 | 2.34 | 2.34 | +123273.29% |
| Q1 2012 | 2012-03-31 | 2.45 | 2.28 | +1337.69% |
| Q4 2011 | 2011-12-31 | 1.93 | 0.93 | +91.76% |
| Q3 2011 | 2011-09-30 | 0.00 | −0.81 | −99.95% |
| Q2 2011 | 2011-06-30 | 0.00 | — | — |
| Q1 2011 | 2011-03-31 | 0.17 | −0.13 | −42.79% |
| Q4 2010 | 2010-12-31 | 1.01 | 0.69 | +212.33% |
| Q3 2010 | 2010-09-30 | 0.81 | — | — |
| Q1 2010 | 2010-03-31 | 0.30 | — | — |
| Q4 2009 | 2009-12-31 | 0.32 | — | — |
Gilead Sciences debt-to-ebitda ratio trends
Over the last five fiscal years, Gilead Sciences's debt-to-ebitda ratio decreased from 5.78 to 2.00, a change of −3.78. The latest reported quarter, Q2 2026, shows 95.79.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
